Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...

Exact Sciences EXAS continues to make significant progress with its Cologuard test and efforts to expand Oncotype DX overseas. Advancements in the key pipeline programs are highly promising.

Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

Exact Sciences and Mayo Clinic collaboratively developed Cologuard Plus, which features novel biomarkers and improved laboratory processes. It also incorporates enhanced sample stability ...

New modelling data from diagnostics company Exact Sciences indicates that its Cologuard test for colorectal cancer (CRC) screening has detected almost 600,000 cases since receiving US Food and ...

Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs. Exact Sciences (EXAS) initiates the ...